Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cantor Fitzgerald
Harvard Business School
Express Scripts
Moodys
Chinese Patent Office

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,039,719

« Back to Dashboard

Which drugs does patent 10,039,719 protect, and when does it expire?

Patent 10,039,719 protects APTENSIO XR and is included in one NDA.

This patent has twelve patent family members in eleven countries.

Summary for Patent: 10,039,719
Title:Methods of treating attention deficit hyperactivity disorder
Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
Inventor(s): Krishnamurthy; Thinnayam N. (Scarborough, CA), Darke; Andrew (Newmarket, CA)
Assignee: RHODES PHARMACEUTICALS L.P. (Coventry, RI)
Application Number:15/714,706
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 10,039,719
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 10,039,719

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-001 Apr 17, 2015 AB3 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Sign Up
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-002 Apr 17, 2015 AB3 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Sign Up
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-003 Apr 17, 2015 AB3 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Argus Health
Deloitte
Merck
Fuji
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.